Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate
| Autor: | Mark L. Vanderwalker, Keith B Nolop, Anjuli Nayak, David F. Graft, Judy E. Harrison, Frank J. Picone, Robert A. Nathan, Tahir Ahmed, James D. Wolfe, Michael S. Lawrence |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Spirometry Adolescent medicine.drug_class Administration Topical animal diseases Immunology Anti-Inflammatory Agents Mometasone furoate Peak Expiratory Flow Rate Placebo law.invention Double-Blind Method Randomized controlled trial law Forced Expiratory Volume Administration Inhalation Humans Immunology and Allergy Medicine Glucocorticoids Pregnadienediols Aged Asthma medicine.diagnostic_test business.industry Beclomethasone virus diseases Middle Aged medicine.disease Metered-dose inhaler Dry-powder inhaler Therapeutic Equivalency Anesthesia Corticosteroid Powders business Mometasone Furoate medicine.drug |
| Zdroj: | Annals of Allergy, Asthma & Immunology. 86:203-210 |
| ISSN: | 1081-1206 |
| DOI: | 10.1016/s1081-1206(10)62692-0 |
| Popis: | Mometasone furoate (MF) is a new inhaled glucocorticoid administered by dry powder inhaler (DPI).MF-DPI was evaluated for safety and efficacy and compared with placebo DPI and beclomethasone dipropionate (BDP) administered by metered dose inhaler (MDI) in the treatment of patients with moderate persistent asthma.Eligible patients (n = 227), 13 to 75 years of age, maintained on inhaled glucocorticoids before entering the trial, were randomized to receive: MF-DPI, 100 microg, twice daily, MF-DPI, 200 microg, twice daily, BDP MDI, 168 microg, twice daily, or placebo in a 12-week, multicenter, double-blind study.At endpoint, FEV1 (primary efficacy variable) significantly improved for all three active treatments compared with placebo (P.01, all comparisons). The response to MF-DPI, 200 microg, twice daily treatment was approximately twice as large as the response to MF-DPI, 100 microg, twice daily or BDP MDI treatment, although the differences between these groups did not reach statistical significance. Secondary efficacy variables including PEFR, asthma symptoms, nocturnal awakenings, and albuterol use showed similar trends. The MF-DPI, 100 microg, twice daily and BDP MDI, 168 microg, twice daily treatment groups produced comparable results for all efficacy variables.MF-DPI, 100 microg and 200 microg, twice daily were well-tolerated and significantly improved lung function and symptom control in the treatment of patients with moderate persistent asthma. In this study, MF-DPI, 200 microg, twice daily seemed to be the most effective dosage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|